Garcia-Rendueles, Maria E. R.
Krishnamoorthy, Gnana
Saqcena, Mahesh
Acuña-Ruiz, Adrian
Revilla, Giovanna
de Stanchina, Elisa
Knauf, Jeffrey A.
Lester, Rona
Xu, Bin
Ghossein, Ronald A.
Fagin, James A.
Funding for this research was provided by:
Comunidad de Madrid (2019T1/BMD13039)
Cycle for Survival
Marie-Josée and Henry R. Kravis Center for Molecular Oncology
National Institute for Health Care Management Foundation (RO1-CA72597)
National Institutes of Health (RO1-CA50706)
Article History
Received: 29 May 2022
Accepted: 25 October 2022
First Online: 7 December 2022
Declarations
:
: Animal care and all experimental procedures were approved by the MSKCC Institutional Animal Care and Use Committee (IACUC).
: Not applicable.
: J.A.F is a consultant for Loxo Oncology, received grant support from Eisai. He is a co-inventor of intellectual property focused on HRAS as a biomarker for treating cancer using tipifarnib which has been licensed by MSK to Kura.